Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason R Westin

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2014
Status of PI3K/Akt/mTOR pathway inhibitors in lymphomaJason R Westin
Future Oncology (London, England)|March 29, 2014
Busting robustness: using cancer's greatest strength to our advantageJason R Westin
Molecular Cancer Therapeutics|December 4, 2012
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapyJason R Westin, Razelle Kurzrock
Leukemia & Lymphoma|April 6, 2011
Vive la résistance: stem cells in mantle cell lymphomaR Eric Davis, Jason R Westin
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2016
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin LymphomaAmir K Issa, Jason R Westin
Leukemia & Lymphoma|November 29, 2021
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Max J Gordon, Jason R Westin
Science (New York, N.Y.)|February 1, 2024
Degradation trumps mutations in cancerR Eric Davis, Jason R Westin
Current Hematologic Malignancy Reports|April 29, 2010
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratificationJason R Westin, Luis E Fayad
Frontiers in Oncology|December 19, 2012
Therapy of newly diagnosed follicular lymphomaJason R Westin, Sattva S Neelapu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic ControlsHua-Jay J Cherng, Jason R Westin
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2014
Status of PI3K/Akt/mTOR pathway inhibitors in lymphomaJason R Westin
Future Oncology (London, England)|March 29, 2014
Busting robustness: using cancer's greatest strength to our advantageJason R Westin
Molecular Cancer Therapeutics|December 4, 2012
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapyJason R Westin, Razelle Kurzrock
Leukemia & Lymphoma|April 6, 2011
Vive la résistance: stem cells in mantle cell lymphomaR Eric Davis, Jason R Westin
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2016
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin LymphomaAmir K Issa, Jason R Westin
Leukemia & Lymphoma|November 29, 2021
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Max J Gordon, Jason R Westin
Science (New York, N.Y.)|February 1, 2024
Degradation trumps mutations in cancerR Eric Davis, Jason R Westin
Current Hematologic Malignancy Reports|April 29, 2010
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratificationJason R Westin, Luis E Fayad
Frontiers in Oncology|December 19, 2012
Therapy of newly diagnosed follicular lymphomaJason R Westin, Sattva S Neelapu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic ControlsHua-Jay J Cherng, Jason R Westin
Pageof 12